转甲状腺素蛋白淀粉样变心肌病门诊心衰恶化:APOLLO-B试验事后分析
APOLLO-B试验事后分析评估转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)门诊心衰恶化(口服利尿剂启用或加量)的预后价值及patisiran疗效。结果显示门诊心衰恶化常见(43.7%),与全因死亡和心血管事件风险升高相关(HR 2.21),patisiran治疗24个月可降低其风险(HR 0.70)。
要点
- 门诊心衰恶化在ATTR-CM患者中发生率达43.7%,与全因死亡和心血管事件风险升高独立相关。
- 将门诊利尿剂启用或加量纳入复合终点可使事件患者数从141增至215(增加52%)。
- patisiran治疗24个月可降低门诊心衰恶化风险(HR 0.70,95%CI 0.51-0.96)。
核心结论
- 在APOLLO-B试验中,ATTR-CM患者门诊心衰恶化频繁发生、具有预后价值,且可被patisiran降低。
研究设计与样本
- APOLLO-B试验(NCT03997383)的事后分析,评估门诊心衰恶化与疾病进展指标及全因死亡和心血管事件复合终点的关联,并分析patisiran治疗24个月(双盲期和开放扩展期)对门诊心衰恶化的影响。
主要发现
- 144例(40.1%)无事件,157例(43.7%)发生门诊心衰恶化,13例(3.6%)需紧急心衰就诊,118例(32.9%)发生心血管住院,47例(13.1%)死亡。
- 门诊心衰恶化与全因死亡和心血管事件风险升高相关(HR 2.21;95%CI 1.58-3.08),并与6分钟步行距离、KCCQ-OS评分和NYHA功能分级恶化更显著及NT-proBNP升高更明显相关。
- 将门诊利尿剂启用或加量加入全因死亡和心血管事件复合终点后,事件患者数从141增至215(增加52%)。
- patisiran在24个月内降低门诊心衰恶化风险(HR 0.70;95%CI 0.51-0.96)。
临床怎么用
- 在ATTR-CM患者随访中,门诊利尿剂启用或加量可作为心衰恶化的预警信号,提示预后不良风险升高。
- patisiran治疗可能有助于减少ATTR-CM患者门诊心衰恶化的发生。
局限性
- 本研究为APOLLO-B试验的事后分析,结果需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outpatient worsening heart failure (HF), defined by initiation or intensification of diuretics, is adversely prognostic for patients with either reduced or preserved ejection fraction. OBJECTIVES: This study sought to investigate the prognostic value of outpatient worsening HF in transthyretin amyloidosis with cardiomyopathy and the effect of patisiran treatment. METHODS: Post hoc analyses of the APOLLO-B trial (NCT03997383) evaluated the associations between outpatient worsening HF (defined by oral diuretic initiation or intensification), measures of disease progression, and a composite endpoint of all-cause mortality and cardiovascular (CV) events. We further examined the effect of patisiran on outpatient worsening HF over 24 months (ie, during the double-blind and open-label extension periods). RESULTS: In APOLLO-B, 144 (40.1%) patients had no event, 157 (43.7%) had outpatient worsening HF, 13 (3.6%) required an urgent HF visit, 118 (32.9%) had a CV hospitalization, and 47 (13.1%) died. Outpatient worsening HF was associated with an increased risk of all-cause mortality and CV events (HR: 2.21; 95% CI: 1.58-3.08), as well as a greater deterioration in 6-minute walk test distance, Kansas City Cardiomyopathy Questionnaire-Overall Summary score, and NYHA functional class and a greater increase in N-terminal prohormone of B-type natriuretic peptide. Addition of outpatient diuretic initiation or intensification to the composite endpoint of all-cause mortality and CV events increased the overall number of patients having an event from 141 to 215 (a 52% increase). Patisiran reduced the risk of outpatient worsening HF (HR: 0.70; 95% CI: 0.51-0.96) over 24 months. CONCLUSIONS: During APOLLO-B, outpatient worsening HF in patients with transthyretin amyloidosis with cardiomyopathy was frequent, prognostic, and reduced by patisiran.
引用
- Fontana, Maurer, Gillmore, et al. Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial. J Am Coll Cardiol. 2025. PMID: 39846936. doi:10.1016/j.jacc.2024.10.097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。